Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus sacituzumab tirumotecan in unresectable EGFR-mutant stage III NSCLC
ChiCTR2600126829Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shandong First Medical University. Primary endpoints: Dose-limiting toxicity (DLT) rate, Incidence of treatment-related Grade ≥3 adverse events and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600126829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126829.